Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenincode Regulatory News (GENI)

Share Price Information for Genincode (GENI)

Share Price is delayed by 15 minutes
Get Live Data
0.90    0.00 (0.00%)
Bid:
0.85
Ask:
0.95
Spread: 0.10 (11.765%)
Market Cap: £6.78m
GENI Live PriceLast checked at - London Stock Exchange

Intraday Genincode Share Chart

Holding(s) in Company

26 Feb 2026 15:30

RNS Number : 5894U
GENinCode PLC
26 February 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BL97B504

Issuer Name

GENINCODE PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

First Equity Limited

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

Name

City of registered office

Country of registered office

Estate of William Black

Armstrong Investments Limited

Douglas

Isle of Man

4. Details of the shareholder

Name

City of registered office

Country of registered office

Nortrust Nominees Limited

London

United Kingdom

5. Date on which the threshold was crossed or reached

25-Feb-2026

6. Date on which Issuer notified

26-Feb-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.780615

0.000000

4.780615

36000000

Position of previous notification (if applicable)

5.311795

0.000000

5.311795

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BL97B504

36000000

0

4.780615

0.000000

Sub Total 8.A

36000000

4.780615%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Estate of William Black

First Equity Limited as Investment Manager of Armstrong Inv Limited

4.780615

4.780615%

Estate of William Black

Armstrong Investments Limited

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

26-Feb-2026

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFFEFAIRFIR
Date   Source Headline
11th Jun 20265:42 pmRNSHolding(s) in Company
10th Jun 20264:53 pmRNSHolding(s) in Company
8th Jun 20267:00 amRNSFinal Results
4th Jun 20266:02 pmRNSHolding(s) in Company
3rd Jun 202611:03 amRNSHolding(s) in Company
22nd May 20267:00 amRNSNotice of Results
8th May 20264:06 pmRNSHolding(s) in Company
7th May 20267:00 amRNSGrant of Share Options & PDMR Dealings
15th Apr 202612:16 pmRNSHolding(s) in Company
14th Apr 20262:09 pmRNSHolding(s) in Company
26th Feb 20263:30 pmRNSHolding(s) in Company
24th Feb 20262:28 pmRNSHolding(s) in Company
12th Feb 20264:07 pmRNSHolding(s) in Company
12th Feb 20263:46 pmRNSHolding(s) in Company
12th Feb 20263:45 pmRNSHolding(s) in Company
9th Feb 202612:13 pmRNSResult of GM, Director Shareholdings and TVR
6th Feb 20262:39 pmRNSAdditional Subscription
26th Jan 20263:00 pmRNSResult of Retail Offer
22nd Jan 20268:24 amRNSResult of Placing and Subscription
21st Jan 20265:26 pmRNSRetail Offer
21st Jan 20265:23 pmRNSPlacing and Subscription
17th Dec 20257:28 amRNSCollaboration with Sohin Genetics
8th Dec 20251:42 pmRNSHolding(s) in Company
4th Dec 20257:00 amRNSCollaboration with Thermo Fisher
3rd Dec 20257:00 amRNSApproval of CARDIO inCode-score in New York state
27th Oct 20257:00 amRNSPublication of Landmark Study in JACC: Advances
13th Oct 20254:21 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
25th Sep 20257:00 amRNSNHS (UCLH) Risk of Ovarian Cancer (ROCA) launch
24th Sep 20255:58 pmRNSHolding(s) in Company
17th Sep 202510:42 amRNSStmnt re Share Price Movement
5th Sep 20257:00 amRNSNotice of Results
26th Aug 20257:00 amRNSTrading update
7th Jul 20257:00 amRNSDe Novo Update – FDA Supervisory Review
30th Jun 202511:42 amRNSResult of AGM
4th Jun 20257:00 amRNSFinal Results
16th May 20257:00 amRNSNotice of Results
30th Apr 20257:00 amRNSDe Novo Submission Update
26th Mar 20257:45 amRNSGrant of Share Options & PDMR Dealings
6th Mar 20252:24 pmRNSHolding(s) in Company
5th Mar 20253:02 pmRNSHolding(s) in Company
4th Mar 20251:16 pmRNSHolding(s) in Company
3rd Mar 202512:54 pmRNSResult of General Meeting, Issue of Equity and TVR
18th Feb 20257:00 amRNSResult of Retail Offer
14th Feb 202510:01 amRNSResult of Placing and Subscription
14th Feb 20257:05 amRNSRetail Offer
14th Feb 20257:00 amRNSPlacing and Subscription
23rd Jan 20257:00 amRNSCARDIO inCode Lab Fee Update & Catalonia Launch
10th Dec 20247:00 amRNSPartnership with Genesupport SA for the ROCA® Test
5th Dec 20247:00 amRNSCARDIO inCode® publication & Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.